growth hormone deficiency (GHD) in children MedDRA version: 9.1 Level: LLT Classification code 10056438 Term: Growth hormone deficiency
Conditions
Interventions
Product Code: NNC 126-0083
Pharmaceutical Form: Powder and solvent for solution for injection
Current Sponsor code: NNC 126-0083
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: e
Sponsors
Novo Nordisk A/S
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the GHD child.) 2. Confirmed diagnosis of growth hormone insufficiency as defined by two different GH provocation tests, defined as a peak of GH level =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Known or suspected allergy to trial product(s) or related products. 2. Previous participation (randomisation) in this trial. 3. Participation in any other clinical trial involving any investigational products within the last three months prior to this trial. 4. Evidence of tumour growth or malignant disease. 5. GHD children with overt diabetes mellitus (fasting blood glucose > 7 mmol/l (126 mg/dL)). 6. GHD children with a history of previous hypoglycaemic episode(s) after cessation of GH treatment. 7. Known chromosomal abnormalities and medical “syndromes” (Turner syndrome, Laron syndrome, Noonan syndrome or absence of growth hormone receptors). 8. Congenital abnormalities (causing skeletal abnormalities), Russell-Silver Syndrome, skeletal dysplasias. 9. Poorly controlled or uncontrolled pituitary insufficiencies of other axes (e.g., thyroid-stimulating hormone, adrenocorticotropic hormone/cortisol, vasopressin deficiency): Children who are on stable replacement therapy for less than 3 months for other hormonal deficiencies prior to enrolment. 10. Major medical conditions and/or presence of contraindication to GH treatment. 11. History of any illnesses or disease that, in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the trial product to the GHD child 12. Clinically significant illness within 4 weeks of dosing. 13. Any clinically significant abnormal haematology or biochemistry screening tests, as judged by the Investigator. 14. Active hepatitis B, measured by surface antigen B (HbsAg) and/or active hepatitis C, measured by positive hepatitis C virus antibody test. 15. Clinically significant abnormal ECG at screening as evaluated by Investigator. 16. Surgery or trauma with significant blood loss within the last 3 months prior to dosing. 17. Mental incapacity of the child, parents/legal guardian or language barriers which preclude adequate understanding or cooperation, who are unwilling to participate in the trial or who in the opinion of their general practitioner or the Investigator should not participate in the trial. 18. The GHD child and/or the parent/legal guardian are likely to be non-compliant in respect to study conduct. 19. Any condition interfering with trial participation or evaluation or that may be hazardous to the GHD child.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine safety and tolerability of single subcutaneous (sc) doses of pegylated long-acting human growth hormone (NNC126-0083) compared to 7 days treatment with sc doses of Norditropin NordiFlex® in growth hormone deficient (GHD) children ;Secondary Objective: To determine pharmacokinetics (PK) and pharmacodynamics (PD) of single sc doses of NNC126-0083 compared to 7 days treatment with sc doses of Norditropin NordiFlex® in GHD children. To compare local tolerability (i.e. injection site reactions) of single sc doses of NNC126-0083 compared to 7 days treatment with sc doses of Norditropin NordiFlex® in GHD children ;Primary end point(s): • Adverse Events • Clinical laboratory safety (haematology, biochemistry and urinalysis) • Fasting glucose • Fasting insulin • Physical examination • Vital signs • Body weight • ECG • Local tolerability • NNC126-0083 antibodies • Human Growth hormone antibodies | — |
Countries
Belgium, Denmark, France, Slovenia, Spain, United Kingdom
Outcome results
None listed